Apontis Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Bruno Wohlschlegel
Chief executive officer
€181.0k
Total compensation
| CEO salary percentage | 59.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce
Oct 17Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?
Jun 18Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€7m |
| Mar 31 2024 | n/a | n/a | -€9m |
| Dec 31 2023 | €181k | €108k | -€11m |
Compensation vs Market: Bruno's total compensation ($USD188.82K) is below average for companies of similar size in the German market ($USD469.16K).
Compensation vs Earnings: Insufficient data to compare Bruno's compensation with company performance.
CEO
Bruno Wohlschlegel (56 yo)
1.3yrs
Tenure
€180,964
Compensation
Mr. Bruno Wohlschlegel serves as Member of Management Board at Apontis Pharma AG since September 01, 2023 and served as its Chief Executive Officer since September 01, 2023. He is Chairman of Management Bo...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | no data | no data | no data | |
| Independent Deputy Chairman of Supervisory Board | 2.6yrs | no data | no data | |
| Independent Chairman of Supervisory Board | 2.6yrs | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 2.6yrs | no data | no data |
2.6yrs
Average Tenure
54yo
Average Age
Experienced Board: APPH's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 21:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apontis Pharma AG is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |
| Tim Wunderlich | Hauck Aufhäuser Investment Banking |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |